Clinical symptoms and laboratory parameters of patients with MI on 28 June–11 August 2020 at NICVD, Dhaka, Bangladesh
| Characteristics | Total of patients with MI (n=280) | SARS-CoV-2 infected (n=36) | No infection (n=244) | P value |
| Symptoms, n (%) | ||||
| Retrosternal chest pain | 166 (59.3.) | 22 (61.1) | 144 (59.0) | 0.811 |
| Fever | 5 (1.8) | 1 (2.8) | 4 (1.6) | 0.630 |
| Cough | 31 (11.1) | 5 (13.9) | 26 (10.7) | 0.564 |
| Shortness of breath | 38 (13.6) | 5 (13.9) | 33 (13.5) | 0.952 |
| Sore throat | 9 (3.2) | 3 (8.3) | 6 (2.5) | 0.062 |
| Runny nose | 2 (0.7) | – | 2 (0.8) | 0.586 |
| Headache | 12 (4.3) | 1 (2.8) | 11 (4.5) | 0.632 |
| Diarrhoea | 6 (2.1) | – | 6 (2.5) | 0.342 |
| Cardiac arrhythmia | 6 (2.1) | 1 (2.8) | 5 (2.1) | 0.778 |
| Body ache | 24 (8.6) | 2 (5.6) | 22 (9.0) | 0.489 |
| Weakness | 131 (46.8) | 23 (63.9) | 108 (44.3) | 0.028* |
| Influenza virus, n (%) | 1 (0.4) | 1 (0.4) | ||
| Type and subtype | A/H3 | – | A/H3 | – |
| SARS-CoV-2, n (%) | 36 (12.9) | 36 (12.9) | – | |
| Cardiac troponin I, pg/mL, median (IQR) | 14 389 (2831–43241) | 10 087 (3548–41005) | 14 529 (2339–43533) | 0.714 |
| Subtype of MI, n (%) | ||||
| Anterior | 38 (27.1) | 5 (27.8) | 33 (27.1) | Ref. |
| Anteroseptal | 31 (22.1) | 3 (16.8) | 28 (23.0) | 0.666 |
| Inferior | 50 (35.7) | 6 (33.3) | 44 (36.1) | 0.872 |
| Extensive anterior | 18 (12.9) | 3 (16.7) | 15 (12.3) | 0.713 |
*Significant at p≤0.05.
MI, myocardial infarction; NICVD, National Institute of Cardiovascular Diseases.